The Finnish pharmaceutical company Orion Pharma has stopped working in the Russian Federation, according to the manufacturer’s report of the first six months. The company makes the hormonal anti-inflammatory drug Metipred (methylprednisolone).
In the first half of the year, the company lost 25 million euros in operating profit compared to the same period of the previous year. Orion connects the losses with the termination of the business in Russia.
Last fall, Vedomosti wrote that Orion had begun to liquidate its office in Russia. Then the sources said that the company massively lays off its employees in the Russian Federation. The manufacturer’s report does not specify exactly when the company left Russia.
Boletín Farmacéutico pointed out that there is no information in the documents that Orion no longer supplies medicines to the country. But according to Roszdravnadzor data, the introduction of the company’s products into circulation has sharply decreased.
Orion Pharma has been operating in Russia for 15 years. In November last year, in response to media reports about the company’s plans to leave the country, Orion’s Russian subsidiary, Orion Corporation, said it was continuing business as usual.
Earlier, the American company Viatris stopped deliveries of Viagra to Russia.
Author:
Natalia Gormaleva
Source: RB
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.